We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · May 25, 2021

Q-TWiST Analysis of Tivozanib vs Sorafenib in Patients With Advanced RCC in the TIVO-3 Study

Clinical Genitourinary Cancer


Additional Info

Clinical Genitourinary Cancer
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Clin Genitourin Cancer 2021 Apr 03;[EPub Ahead of Print], M Szarek, MN Needle, BI Rini, SK Pal, DF McDermott, MB Atkins, TE Hutson, BJ Escudier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading